Antibacterial-induced nephrotoxicity in the newborn

Area of Science:

• Nephrology
• Pharmacology
• Neonatal Medicine

Background:

• Drug-induced kidney disease is a significant concern across all age groups, with antibacterials being a primary cause.
• Nephrotoxicity from antibacterials occurs via direct or immunologically mediated mechanisms.
• The incidence of acute renal failure from commonly used antibacterials like aminoglycosides and vancomycin is increasing in newborns.

Purpose of the Study:

• To highlight the importance of antibacterial-induced nephrotoxicity in neonatal care.
• To emphasize the need for early, non-invasive markers of renal damage, as traditional parameters only indicate substantial injury.
• To review the nephrotoxic potential of various antibacterial classes in neonates.

Main Methods:

• Review of existing literature on antibacterial-induced nephrotoxicity.
• Analysis of mechanisms of renal damage caused by different antibacterial classes.
• Discussion on the role of neonatal age and combined drug therapies in nephrotoxicity.

Main Results:

• Aminoglycosides and vancomycin frequently cause nephrotoxicity, which is often reversible but can lead to acute renal failure, particularly in neonates.
• Beta-lactams and related compounds exhibit varying nephrotoxicity, with carbapenems posing the highest risk and monobactams the lowest.
• Third-generation cephalosporins, commonly used in neonates, are generally well-tolerated renally.

Conclusions:

• Antibacterial-induced nephrotoxicity is a critical consideration in neonatal treatment, especially with combination therapies.
• Identifying early, non-invasive biomarkers for renal damage is essential for timely intervention.
• Balancing antibacterial efficacy with renal safety, alongside pharmacokinetic and clinical factors, is vital for optimal neonatal care.